Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma, Non-Hodgkin: early-phase trial registry
16 of 62 indexed Lymphoma, Non-Hodgkin trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #228 of 28,707 conditions by registered trial count.
62 US clinical trials · 16 currently recruiting · #228 of 28,707 conditions by registered trial count
Lymphoma, Non-Hodgkin: 62 US clinical trials tracked, 16 recruiting.
Lymphoma, Non-Hodgkin is the subject of 62 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 44 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition lymphoma-non-hodgkin
OPEN 16 | RECR 26% | LATE 5 | EARLY 44 | RANK #228 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Diabetic Retinopathy (26% recruiting · 58 trials)
Lymphoma, Non-Hodgkin lists 16 open slots (26% of 62 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma, Non-Hodgkin on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma, Non-Hodgkin is recruiting below its size-band peers.
16 of 62 indexed trials (25.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lymphoma, Non-Hodgkin trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 5 of 62 trials (8.1%). 45 distinct sponsors appear on at least one study for this condition label.
-
Typical Lymphoma, Non-Hodgkin enrolment sits around 67 participants.
Median target enrolment is 67 among the 59 trials that report a genuine target (sentinel values excluded). 33 of those (55.9%) plan for fewer than 100 participants.
-
Lymphoma, Non-Hodgkin research is mostly interventional.
54 interventional and 8 observational studies make up this index (87.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
62 total, page 1 of 2
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Stanford University
NCT00398177
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
American Society of Clinical Oncology
NCT02693535
Family Study of Lymphoproliferative Disorders
Mayo Clinic
NCT00626496
Tissue Collection for Studies of Lymph Cancer
National Cancer Institute (NCI)
NCT01676805
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
National Cancer Institute (NCI)
NCT02682667
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development
NCT05421663
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Dizal Pharmaceuticals
NCT05824585
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Treeline Biosciences
NCT07082803
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine
NCT06022029
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT05442515
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Caribou Biosciences
NCT04637763
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
NCT05618366
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Beth Israel Deaconess Medical Center
NCT06510361
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Abramson Cancer Center at Penn Medicine
NCT06458439
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Dana-Farber Cancer Institute
NCT06923397
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
NCT05800210
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Memorial Sloan Kettering Cancer Center
NCT00579163
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT04077723
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Celgene
NCT03930953
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
NCT05024045
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland
NCT03229200
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Celgene
NCT04245839
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development
NCT05424822
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta
NCT05020678
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
NCT03301168
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
Ono Pharmaceutical Co.
NCT05515406
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
University of Miami
NCT05968963
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT05540340
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
NCT02690545
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
NCT04975555
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
NCT03480360
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Washington University School of Medicine
NCT00882895
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT02663297
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
Baylor College of Medicine
NCT00368082
A Study of Patients With AIDS Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001120
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
National Cancer Institute (NCI)
NCT00339963
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Stanford University
NCT00398372
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Bayer
NCT02367040
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000658
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Pfizer
NCT01307267
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Merck Sharp & Dohme
NCT03598608
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Washington University School of Medicine
NCT00241358
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Pfizer
NCT00141297
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
Abbott
NCT00061672
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
Washington University School of Medicine
NCT00733824
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Novartis Pharmaceuticals
NCT01294579
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
ImmunoGen
NCT01534715
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000703
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
National Heart, Lung, and Blood Institute (NHLBI)
NCT01866839
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Genzyme, a Sanofi Company
NCT00322387
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 14 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma, Non-Hodgkin records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma, Non-Hodgkin trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma, Non-Hodgkin page
62 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Lymphoma, Non-Hodgkin trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Lymphoma, Non-Hodgkin trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma, Non-Hodgkin condition card totals 62 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.